EARLY Study

What we are studying

The purpose of this research study is to determine whether an investigational drug, JNJ-54861911 is safe and beneficial in treating participants who are at risk of developing Alzheimer's disease. This study will last for about 5 years. During this time, participants will be given either active study drug, JNJ-54861911 or placebo. A study partner is needed to participate.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 60 - 85

Eligibility Criteria

  • Participants must be able to read and write
  • Be considered healthy for their age group
  • Stable on medications
  • Have a reliable study partner
  • Must be willing to have a PET scan or lumbar puncture and take study drug.

What is involved

  • There will be at least 31 in-person visits over 5 years
  • Memory and behavior questionnaires
  • 6 MRI scans
  • 3 PET scans or 3 lumbar punctures
  • 25 blood draws
  • 2 dermatological exams and 13 ECGs .

Compensation

Screening Visit 1 $50.00 Screening Visit 2, Screening Visits 5 & 6 $25.00 each visit Screening Visits 3 & 4, Study Visits 7, 13, 17, 19, 21, 25, 26, 29 & 31 $75.00 each visit Study Visits 8, 9, 10, 11, 12, 14, 15, 16, 18, 20, 22, 23, 24, 27, 28, 30

Contact Information

Study Coordinator
Cory Dix
Email
cdix@wakehealth.edu
Phone
336-716-6463
Principal Investigator
Kaycee Sink, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.